Intracellular Operating Margin from 2010 to 2024
| ITCI Stock | USD 85.69 0.24 0.28% |
Check Intracellular financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Intracellular's main balance sheet or income statement drivers, such as Interest Expense of 8.9 M, Total Revenue of 487.6 M or Gross Profit of 452.2 M, as well as many indicators such as Price To Sales Ratio of 14.05, Dividend Yield of 0.0 or PTB Ratio of 7.67. Intracellular financial statements analysis is a perfect complement when working with Intracellular Valuation or Volatility modules.
Intracellular | Operating Margin |
Latest Intracellular's Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of Intracellular Th over the last few years. It is Intracellular's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Intracellular's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (0.22) % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
Intracellular Operating Margin Regression Statistics
| Arithmetic Mean | (474.03) | |
| Coefficient Of Variation | (188.59) | |
| Mean Deviation | 642.38 | |
| Median | (9.60) | |
| Standard Deviation | 894.00 | |
| Sample Variance | 799,228 | |
| Range | 2.5K | |
| R-Value | (0.08) | |
| Mean Square Error | 854,614 | |
| R-Squared | 0.01 | |
| Significance | 0.77 | |
| Slope | (16.82) | |
| Total Sum of Squares | 11.2M |
Intracellular Operating Margin History
About Intracellular Financial Statements
Investors use fundamental indicators, such as Intracellular's Operating Margin, to determine how well the company is positioned to perform in the future. Although Intracellular's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York. Intra-Cellular Ther operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 512 people.
Currently Active Assets on Macroaxis
When determining whether Intracellular Th offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Intracellular's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Intracellular Th Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Intracellular Th Stock:Check out the analysis of Intracellular Correlation against competitors. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intracellular. If investors know Intracellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intracellular listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.87) | Revenue Per Share 6.096 | Quarterly Revenue Growth 0.39 | Return On Assets (0.07) | Return On Equity (0.1) |
The market value of Intracellular Th is measured differently than its book value, which is the value of Intracellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intracellular's value that differs from its market value or its book value, called intrinsic value, which is Intracellular's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intracellular's market value can be influenced by many factors that don't directly affect Intracellular's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intracellular's value and its price as these two are different measures arrived at by different means. Investors typically determine if Intracellular is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intracellular's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.